This company listing is no longer active
Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
ACGN Aktienübersicht
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Aceragen, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.38 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$0.36 |
| Beta | 1.14 |
| 1 Month Change | -48.99% |
| 3 Month Change | -76.54% |
| 1 Year Change | -95.55% |
| 3 Year Change | -98.96% |
| 5 Year Change | -99.78% |
| Change since IPO | -100.00% |
Aktuelle Nachrichten und Updates
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Aktionärsrenditen
| ACGN | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -11.6% | 1.9% | 1.3% |
| 1Y | -95.5% | 6.7% | 21.0% |
Rendite im Vergleich zur Industrie: ACGN underperformed the US Biotechs industry which returned 6.3% over the past year.
Rendite vs. Markt: ACGN underperformed the US Market which returned 4.2% over the past year.
Preisvolatilität
| ACGN volatility | |
|---|---|
| ACGN Average Weekly Movement | 23.7% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.8% |
Stabiler Aktienkurs: ACGN's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: ACGN's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1989 | 26 | John Taylor | www.aceragen.com |
Aceragen, Inc.'s Grundlagenzusammenfassung
| ACGN grundlegende Statistiken | |
|---|---|
| Marktanteil | US$3.20m |
| Gewinn(TTM) | -US$41.05m |
| Umsatz(TTM) | US$7.33m |
0.4x
Kurs-Umsatz-Verhältnis-0.1x
Kurs-Gewinn-VerhältnisIst ACGN zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ACGN Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$7.33m |
| Kosten der Einnahmen | US$15.40m |
| Bruttogewinn | -US$8.06m |
| Sonstige Ausgaben | US$32.98m |
| Umsatz | -US$41.05m |
Zuletzt gemeldete Gewinne
Mar 31, 2023
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -4.88 |
| Bruttomarge | -110.00% |
| Nettogewinnspanne | -559.86% |
| Schulden/Eigenkapital-Verhältnis | 1.3% |
Wie hat sich ACGN auf lange Sicht entwickelt?
Historische Performance und Vergleiche